M. M. Weissman, L. Bruce, P. J. Leaf, L. Florio, C. A. Holzer et al., Psychiatric Disorders in America. The Epidemiologic Catchment Area Study, pp.53-80, 1991.

R. Kessler, The National Comorbidity Survey of the United States, Int Rev Psychiatry, vol.6, pp.365-376, 1994.

K. R. Merikangas, H. S. Akiskal, and J. Angst, Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry, vol.64, pp.543-552, 2007.

L. Kleinman, A. Lowin, E. Flood, G. Gandhi, E. Edgell et al., Costs of bipolar disorder, Pharmacoeconomics, vol.21, issue.9, pp.601-622, 2003.

P. E. Greenberg, R. C. Kessler, and H. G. Birnbaum, The economic burden of depression in the United States: how did it change between 1990 and, J Clin Psychiatry, vol.64, issue.12, pp.1465-1475, 2000.

, Bipolar Disorder. The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. National Collaborating Centre for Mental Health ed. The British Psychological Society and The Royal College of Psychiatrists, 2006.

M. Sajatovic, S. Madhusoodanan, M. A. Fuller, L. Aulakh, and D. B. Keaton, Risperidone for bipolar disorders, Expert Rev Neurother, 2005.

E. Vieta, J. M. Goikolea, and B. Corbella, Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study, J Clin Psychiatry, vol.62, issue.10, pp.818-825, 2001.

C. Guille, G. S. Sachs, and S. N. Ghaemi, A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder, J Clin Psychiatry, vol.61, issue.9, pp.638-642, 2000.

A. B. Smulevich, S. Khanna, M. Eerdekens, K. Karcher, M. Kramer et al., Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week doubleblind trial of risperidone and haloperidol, Eur Neuropsychopharmacol, vol.15, issue.1, pp.75-84, 2005.

P. E. Keck, J. R. Calabrese, and R. S. Mcintyre, Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo, J Clin Psychiatry, vol.68, issue.10, pp.1480-1491, 2007.

D. J. Muzina, C. Momah, and J. M. Eudicone, Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study, Int J Clin Pract, vol.62, issue.5, pp.679-687, 2008.

E. Vieta, T. Suppes, I. Eggens, I. Persson, B. Paulsson et al., Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126), J Affect Disord, vol.109, issue.3, pp.251-263, 2008.

T. Suppes, E. Vieta, S. Liu, M. Brecher, and B. Paulsson, Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex, vol.127

, Am J Psychiatry, vol.166, issue.4, pp.476-488, 2009.

A. Duffy, R. Milin, and P. Grof, Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine, BMC Psychiatry, vol.9, p.4, 2009.

A. Cipriani, J. M. Rendell, and J. Geddes, Olanzapine in long-term treatment for bipolar disorder, Cochrane Database Syst Rev, issue.1, p.4367, 2009.

P. Grof, Selecting effective long-term treatment for bipolar patients: monotherapy and combinations, J Clin Psychiatry, vol.64, issue.5, pp.53-61, 2003.

M. Sajatovic, K. Biswas, A. K. Kilbourne, H. Fenn, W. Williford et al., Factors associated with prospective long-term treatment adherence among individuals with bipolar disorder, Psychiatr Serv, 2008.

F. D. Gianfrancesco, K. Rajagopalan, M. Sajatovic, and R. H. Wang, Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics, J Clin Psychiatry, vol.67, issue.2, pp.222-232, 2006.

M. X. Patel, M. Taylor, and A. S. David, Antipsychotic long-acting injections: mind the gap, Br J Psychiatry, vol.195, issue.52, pp.1-4, 2009.

L. Citrome, Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic, Int J Clin Pract, vol.63, issue.1, pp.140-150, 2009.

D. E. Kemp, F. Canan, B. I. Goldstein, and R. S. Mcintyre, Long-acting risperidone: a review of its role in the treatment of bipolar disorder, Adv Ther, vol.26, issue.6, pp.588-599, 2009.

L. Ereshefsky and C. A. Mascarenas, Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics, J Clin Psychiatry, vol.64, pp.18-23, 2003.

M. Eerdekens, H. I. Van, B. Remmerie, and E. Mannaert, Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia, Schizophr Res, vol.70, issue.1, pp.91-100, 2004.

R. Nesvag, M. Hendset, H. Refsum, and L. Tanum, Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication

, Acta Psychiatr Scand, vol.114, issue.1, pp.21-26, 2006.

S. Nyberg, B. Eriksson, G. Oxenstierna, C. Halldin, and L. Farde, Suggested Minimal Effective Dose of Risperidone Based on PET-Measured D2 and 5-HT2A Receptor Occupancy in Schizophrenic Patients, Am J Psychiatry, vol.156, issue.6, pp.869-875, 1999.

O. Gefvert, B. Eriksson, and P. Persson, Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia, Int J Neuropsychopharmacol, vol.8, issue.1, pp.27-36, 2005.

S. A. Surguladze, E. M. Chu, and A. Evans, The effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study, J Clin Psychopharmacol, vol.27, issue.6, pp.560-570, 2007.

S. A. Surguladze, E. M. Chu, and N. Marshall, Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication, Journal of Psychopharmacology, 2010.

L. E. Van-beijsterveldt, R. J. Geerts, and J. E. Leysen, Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat, Psychopharmacology (Berl), vol.114, issue.1, pp.53-62, 1994.

M. Aravagiri and S. R. Marder, Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats, Psychopharmacology (Berl), vol.159, issue.4, pp.424-431, 2002.

J. M. Kane, E. Aguglia, and A. C. Altamura, Guidelines for depot antipsychotic treatment in schizophrenia, European Neuropsychopharmacology Consensus Conference in, vol.8, pp.55-66, 1998.

M. Riedel, M. J. Schwarz, and M. Strassnig, Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci, vol.255, pp.261-268, 2005.

A. Thyssen, S. Rusch, V. Herben, J. Quiroz, and E. Mannaert, Risperidone Long-Acting Injection: Pharmacokinetics Following Administration in Deltoid Versus Gluteal Muscle in Schizophrenic Patients, J Clin Pharmacol, 2010.

R. N. Malempati, D. J. Bond, and L. N. Yatham, Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients, Int Clin Psychopharmacol, vol.23, issue.2, pp.88-94, 2008.

C. Han, M. S. Lee, C. U. Pae, Y. H. Ko, A. A. Patkar et al., Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.31, pp.1219-1223, 2007.

A. Mohl, K. Westlye, and S. Opjordsmoen, Long-acting risperidone in stable patients with schizoaffective disorder, J Psychopharmacol, issue.5, pp.22-31, 2005.

, This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here

, Neuropsychiatric Disease and Treatment, p.6, 2010.

S. El-hage,

A. Camacho, B. Ng, B. Galangue, and D. Feifel, Use of risperidone long-acting injectable in a rural border community clinic in southern california. Psychiatry (Edgmont ), vol.5, pp.43-49, 2008.

O. S. Niaz and P. M. Haddad, Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirrorimage analysis of in-patient care, Acta Psychiatr Scand, vol.116, issue.1, pp.36-46, 2007.

D. Taylor, Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review, Br J Psychiatry, vol.195, issue.52, pp.13-19, 2009.

A. Benabarre, P. Castro, and J. Sanchez-moreno, Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder

, Actas Esp Psiquiatr, vol.37, issue.3, pp.143-147, 2009.

L. N. Yatham, A. Fallu, and C. E. Binder, A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder, Acta Psychiatr Scand Suppl, issue.434, pp.50-56, 2007.

H. A. Savas, M. Yumru, and M. E. Ozen, Use of long-acting risperidone in the treatment of bipolar patients, J Clin Psychopharmacol, 2006.

E. Vieta, E. Nieto, and A. Autet, A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone, World J Biol Psychiatry, vol.9, issue.3, pp.219-224, 2008.

W. Macfadden, L. Alphs, and J. T. Haskins, A randomized, doubleblind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently, Bipolar Disord, vol.11, issue.8, pp.827-839, 2009.

D. V. Jeste, G. S. Alexopoulos, and S. J. Bartels, Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry, vol.56, pp.848-853, 1999.

R. M. Hirschfeld, J. R. Calabrese, and M. M. Weissman, Screening for bipolar disorder in the community, J Clin Psychiatry, vol.64, issue.1, pp.53-59, 2003.

D. Singh, O. Connor, and D. W. , Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia, Clin Interv Aging, vol.4, pp.351-355, 2009.

W. Kissling, P. Glue, R. Medori, and S. Simpson, Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients, Hum Psychopharmacol, vol.22, issue.8, pp.505-513, 2007.

D. M. Taylor, C. Fischetti, A. Sparshatt, A. Thomas, D. Bishara et al., Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice, J Clin Psychiatry, vol.70, issue.2, pp.196-200, 2009.

M. Sajatovic, J. H. Jenkins, K. A. Cassidy, and D. J. Muzina, Medication treatment perceptions, concerns and expectations among depressed individuals with Type I Bipolar Disorder, J Affect Disord, vol.115, issue.3, pp.360-366, 2009.

T. Burns, Knowledge about antipsychotic long-acting injections: bridging that gap, Br J Psychiatry, vol.195, issue.52, pp.5-6, 2009.